RVL Pharmaceuticals PLC RVLP

Market cap
$14.1M
P/E
0.0×
Jun '23 Mar '23 Dec '22 Sep '22 Older periods
ROE
(182.44%) (103.18%) (80.88%) (86.13%)

+8 more TTM periods

ROA
(64.94%) (44.23%) (37.84%) (40.09%)
ROIC
(80.54%) (61.84%) (58.06%) (55.09%)
Return on Tangible Assets
174.15% (231.19%) (134.17%) (105.97%)
Average Days of Receivables
19.10 18.48 22.25 27.99
Free Cash Flow per Share
(0.48) (0.33) (0.43) (0.49)
Free Cash Flow
(47.41) (32.34) (38.56) (45.64)
Capital Expenditures
(3.00) (1.99) (0.75) 0.13
Piotroski F-Score
2.00 2.00 3.00 4.00
Other line items
Cash ROIC
(47.63%) (23.38%) (24.78%) (24.78%)
Accounts Receivable Turnover
19.61 3.82 19.26 11.45
Accounts Payable Turnover
2.34 2.61 3.06 1.39
Inventory Turnover
9.90 18.29 11.66 11.04
Average Days of Payables
98.98 99.88 92.91 320.35
Days of Inventory on Hand
53.05 8.09 30.26 28.41
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
8.40% 10.05% 7.98% 9.87%
Selling, General and Administrative Expense of Revenue
184.35% 200.34% 164.88% 205.90%
Share Based Compensation of Revenue
6.45% 9.05% 8.19% 9.77%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
0.65 0.54 0.73 0.86
Depreciation/Fixed assets
8.91 6.35 13.13 2.94
Capex/Depreciation
(0.10) (0.13) (0.04) 0.07
Revenue per Share
0.37 0.37 0.55 0.46
Operating CF per Share
(0.45) (0.31) (0.42) (0.49)
Capex per Share
(0.03) (0.02) (0.01) 0.00
Capex to Sales
0.08 0.05 0.02 0.00
Net Profit Margin
(184.91%) (152.21%) (103.96%) (124.13%)

Fold the line items

Columns are period end dates